eyecro COO Gives Talk at ARVO

We are proud to announce a significant breakthrough in ophthalmic care: our innovative MiDROPS® technology has been validated for safety and efficacy in its first clinical application. Data from the technology’s first clinical application is being presented at the 96th meeting of the Association for Research in Vision and Ophthalmology in Seattle, WA. Read the…

We’re proud to share that EyeCRO CEO Dr. Rafal Farjo is a co-author on a new publication validating a cell-based potency assay for LUXTURNA®, the first gene therapy approved in the U.S. for an inherited retinal disease. As stated in the publication: “This represents the first report of validation studies supporting an in vitro cell-based…

When a preclinical efficacy study wraps up at EyeCRO, ocular tissues move directly from our animal facility to our bioanalytical lab. No third-party handoffs. No waiting in an external lab’s queue. Sponsors receive a single integrated dataset covering both in-life endpoints and bioanalytical quantitation from the team that ran the entire study. LC-MS/MS Quantitation Our…

A new study from the National Institutes of Health (NIH) has shown promising results for reserpine—a medication originally approved in 1955 for high blood pressure—as a potential treatment to prevent vision loss caused by inherited blinding diseases such as retinitis pigmentosa. In preclinical studies, reserpine protected retinal neurons essential for vision, particularly in females. Unlike…

EyeCRO is thrilled to announce the first clinical application of our groundbreaking MiDROPS® technology.

EyeCRO LLC has been awarded full accreditation from AAALAC International for their facility in Oklahoma City, OK. EyeCRO joins the Department of Veterans Affairs, the Oklahoma Medical Research Foundation, Oklahoma State University, and the University of Oklahoma Health Sciences Center as the fifth institution in Oklahoma to receive this prestigious endorsement. The award letter from…